Common reasons include mask discomfort, air leakage, skin irritation, claustrophobia, nasal congestion from pressurized air, aerophagia (swallowing air causing bloating), noise, difficulty traveling with the machine, and partner disturbance. About half of patients prescribed CPAP stop using it within the first year. Many try multiple mask styles before giving up.

For most patients with mild to moderate OSA, a custom mandibular advancement device (oral appliance) is the best CPAP alternative. It is silent, portable, comfortable, and has significantly higher compliance rates. For severe OSA, the best alternative may be combination therapy (oral appliance + lower-pressure CPAP), surgical options (maxillomandibular advancement, hypoglossal nerve stimulation), or positional therapy if the apnea is position-dependent.

Most medical insurance plans cover oral appliances for diagnosed OSA. Coverage often requires documentation that CPAP was tried and was either inadequate or not tolerated. Some plans cover oral appliances as first-line therapy for mild to moderate OSA without requiring prior CPAP trial. ADSC handles the pre-authorization process and documentation.

CPAP eliminates more apnea events per hour. But oral appliances produce comparable health outcomes (blood pressure reduction, cardiovascular risk reduction, quality-of-life improvement) because patients use them more consistently. A device used every night for seven hours is more effective in practice than one used half the nights for four hours.

Combination therapy uses a mandibular advancement device together with a CPAP machine set to a lower pressure. The oral appliance opens the airway partially, allowing the CPAP to operate at reduced pressure (often 4 to 8 cm H2O instead of 12+). This reduction in pressure often makes CPAP tolerable for patients who found the required high pressures unbearable.

Significant weight loss (typically 10 percent or more of body weight) can reduce OSA severity, sometimes enough to eliminate the need for treatment. However, most patients with structural anatomical factors (jaw position, palatal width) retain some degree of OSA regardless of weight. Weight management is an important adjunct, not a replacement, for primary OSA therapy in most cases.

Inspire is a surgically implanted device that stimulates the hypoglossal nerve during sleep, causing the tongue to stiffen and move forward with each breath — preventing airway collapse. It is FDA-approved for moderate to severe OSA in patients who cannot tolerate CPAP and meet specific anatomical criteria. Evaluation and implantation are performed by ENT surgeons; ADSC can coordinate referral when this option is clinically appropriate.

For patients with positional OSA — where the AHI is at least twice as high when sleeping supine (on the back) compared to lateral (on the side) — positional therapy devices that discourage back-sleeping can meaningfully reduce the AHI. These range from simple bumper belts to electronic vibrating monitors. Positional therapy is most effective for mild OSA and as an adjunct to other treatments.

Maxillomandibular advancement surgery (advancing both jaws) is the most effective surgical treatment, achieving OSA cure in 85 to 90 percent of cases. Other surgeries (UPPP, tonsillectomy, tongue base reduction) have variable success rates. Surgery is generally reserved for patients who cannot tolerate CPAP or oral appliances, or whose anatomy specifically indicates a surgical approach.

Bring your sleep study results and CPAP usage documentation to a consultation at ADSC. If you have not had a sleep study, the team coordinates diagnostic testing. If CPAP intolerance is documented, medical insurance authorization for oral appliance therapy is initiated. The clinical evaluation determines which alternative treatment is most appropriate for your OSA severity and anatomy.

Myofunctional therapy — exercises that strengthen the tongue, soft palate, and oropharyngeal muscles — has demonstrated AHI reduction of approximately 50 percent in mild to moderate OSA in clinical trials. It is most effective as an adjunct to primary therapy (oral appliance or CPAP) and for patients whose airway collapse is related to poor neuromuscular tone rather than structural skeletal factors.

No. Untreated moderate to severe OSA significantly increases the risk of hypertension, heart failure, stroke, cardiac arrhythmia, diabetes, depression, and motor vehicle accidents. The chronic oxygen desaturation and sleep fragmentation create cumulative cardiovascular and neurocognitive damage. Any effective treatment — CPAP, oral appliance, or surgery — is substantially safer than no treatment.

Yes. Mandibular advancement devices are highly effective for primary snoring (snoring without apnea), though medical insurance typically does not cover treatment for snoring alone. Patients who snore loudly but have a normal AHI on sleep testing may choose oral appliance therapy for the snoring benefit, with the understanding that the cost is out-of-pocket.

Ask whether oral appliance therapy is appropriate for your OSA severity. Ask whether a CPAP alternative trial can be authorized by your insurance. Ask about combination therapy if your required CPAP pressure is uncomfortably high. Ask for a referral to a dental sleep medicine provider. If your sleep physician is unfamiliar with oral appliance therapy, ADSC can initiate the collaborative relationship.

Oral appliances alone may not adequately treat severe OSA (AHI above 30). Combination therapy (oral appliance plus reduced-pressure CPAP), surgical options, or Inspire implant may be more appropriate. However, some patients with severe OSA achieve significant AHI reduction with oral appliances — treatment response is individual. Follow-up sleep testing determines whether the achieved reduction is clinically adequate.